Matthew F Crum1, Natalie L Trevaskis1, Hywel D Williams1,2, Colin W Pouton1, Christopher J H Porter3,4. 1. Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia. 2. Capsugel R&D Australia, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia. 3. Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia. chris.porter@monash.edu. 4. ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC, 3052, Australia. chris.porter@monash.edu.
Abstract
PURPOSE: In vitro lipid digestion models are commonly used to screen lipid-based formulations (LBF), but in vitro-in vivo correlations are in some cases unsuccessful. Here we enhance the scope of the lipid digestion test by incorporating an absorption 'sink' into the experimental model. METHODS: An in vitro model of lipid digestion was coupled directly to a single pass in situ intestinal perfusion experiment in an anaesthetised rat. The model allowed simultaneous real-time analysis of the digestion and absorption of LBFs of fenofibrate and was employed to evaluate the influence of formulation digestion, supersaturation and precipitation on drug absorption. RESULTS: Formulations containing higher quantities of co-solvent and surfactant resulted in higher supersaturation and more rapid drug precipitation in vitro when compared to those containing higher quantities of lipid. In contrast, when the same formulations were examined using the coupled in vitro lipid digestion - in vivo absorption model, drug flux into the mesenteric vein was similar regardless of in vitro formulation performance. CONCLUSION: For some drugs, simple in vitro lipid digestion models may underestimate the potential for absorption from LBFs. Consistent with recent in vivo studies, drug absorption for rapidly absorbed drugs such as fenofibrate may occur even when drug precipitation is apparent during in vitro digestion.
PURPOSE: In vitro lipid digestion models are commonly used to screen lipid-based formulations (LBF), but in vitro-in vivo correlations are in some cases unsuccessful. Here we enhance the scope of the lipid digestion test by incorporating an absorption 'sink' into the experimental model. METHODS: An in vitro model of lipid digestion was coupled directly to a single pass in situ intestinal perfusion experiment in an anaesthetised rat. The model allowed simultaneous real-time analysis of the digestion and absorption of LBFs of fenofibrate and was employed to evaluate the influence of formulation digestion, supersaturation and precipitation on drug absorption. RESULTS: Formulations containing higher quantities of co-solvent and surfactant resulted in higher supersaturation and more rapid drug precipitation in vitro when compared to those containing higher quantities of lipid. In contrast, when the same formulations were examined using the coupled in vitro lipid digestion - in vivo absorption model, drug flux into the mesenteric vein was similar regardless of in vitro formulation performance. CONCLUSION: For some drugs, simple in vitro lipid digestion models may underestimate the potential for absorption from LBFs. Consistent with recent in vivo studies, drug absorption for rapidly absorbed drugs such as fenofibrate may occur even when drug precipitation is apparent during in vitro digestion.
Entities:
Keywords:
absorption; drug solubilisation; in situ intestinal perfusion; lipid-based drug delivery systems; supersaturation
Authors: Thao Thi Do; Michiel Van Speybroeck; Raf Mols; Pieter Annaert; Johan Martens; Jan Van Humbeeck; Jan Vermant; Patrick Augustijns; Guy Van den Mooter Journal: Int J Pharm Date: 2011-05-07 Impact factor: 5.875
Authors: Yan Yan Yeap; Jaclyn Lock; Sean Lerkvikarn; Tanner Semin; Nicholas Nguyen; Rebecca L Carrier Journal: J Control Release Date: 2018-12-06 Impact factor: 9.776
Authors: Peng Li; Leigh Ford; Shadabul Haque; Mitchell P McInerney; Hywel D Williams; Peter J Scammells; Philip E Thompson; Vincent Jannin; Christopher J H Porter; Hassan Benameur; Colin W Pouton Journal: Pharm Res Date: 2021-06-07 Impact factor: 4.200